ECSP077246A - Formulaciones Estabilizadoras - Google Patents
Formulaciones EstabilizadorasInfo
- Publication number
- ECSP077246A ECSP077246A EC2007007246A ECSP077246A ECSP077246A EC SP077246 A ECSP077246 A EC SP077246A EC 2007007246 A EC2007007246 A EC 2007007246A EC SP077246 A ECSP077246 A EC SP077246A EC SP077246 A ECSP077246 A EC SP077246A
- Authority
- EC
- Ecuador
- Prior art keywords
- protein
- storing
- methods
- relatively low
- formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Se describen formulaciones que son adecuadas para el almacenamiento de proteínas, tal como anticuerpos, sobre un rango relativamente amplio de concentraciones de proteína, pH, y tipos de tampón. También se describen métodos de almacenamiento de una proteína y métodos para identificar una formulación adecuada para el almacenamiento de una proteína específica. En general, una formulación que contiene poco o nada de surfactante, desde nada a concentraciones relativamente bajas de sal, y que requiere una concentración de tampón relativamente baja.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60131104P | 2004-08-13 | 2004-08-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP077246A true ECSP077246A (es) | 2007-05-30 |
Family
ID=35908214
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2007007246A ECSP077246A (es) | 2004-08-13 | 2007-02-13 | Formulaciones Estabilizadoras |
Country Status (18)
Country | Link |
---|---|
US (1) | US8871201B2 (es) |
EP (1) | EP1784219B1 (es) |
JP (1) | JP4948407B2 (es) |
KR (1) | KR20070092197A (es) |
CN (1) | CN101022831A (es) |
AR (1) | AR051009A1 (es) |
AU (1) | AU2005272603A1 (es) |
BR (1) | BRPI0514340A (es) |
CA (1) | CA2575870A1 (es) |
CR (1) | CR8904A (es) |
EC (1) | ECSP077246A (es) |
ES (1) | ES2637854T3 (es) |
IL (1) | IL181265A0 (es) |
MX (1) | MX2007001599A (es) |
NO (1) | NO20070930L (es) |
RU (1) | RU2007109062A (es) |
TW (1) | TW200621282A (es) |
WO (1) | WO2006020935A2 (es) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
BRPI0611901A2 (pt) | 2005-06-14 | 2012-08-28 | Amgen, Inc | composição, liofilizado, kit, e, processo para preparar uma composição |
CA2649538C (en) * | 2006-04-21 | 2014-06-03 | Yatin Gokarn | Buffering agents for biopharmaceutical formulations |
NZ571757A (en) | 2006-04-21 | 2012-01-12 | Novartis Ag | Antagonist anti-CD40 antibody pharmaceutical compositions comprising arginine-HCl and a citrate or citric acid buffer |
US20080070230A1 (en) * | 2006-06-12 | 2008-03-20 | Wyeth | Methods for reducing or preventing liquid-liquid phase separation in high concentration protein solutions |
EP1950225A1 (de) * | 2007-01-25 | 2008-07-30 | Octapharma AG | Verfahren zur Steigerung von Proteinausbeuten |
MX2009010361A (es) | 2007-03-29 | 2009-10-16 | Abbott Lab | Anticuerpos il-12 anti-humanos cristalinos. |
US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
US8420081B2 (en) * | 2007-11-30 | 2013-04-16 | Abbvie, Inc. | Antibody formulations and methods of making same |
US20100172862A1 (en) * | 2008-11-28 | 2010-07-08 | Abbott Laboratories | Stable antibody compositions and methods of stabilizing same |
WO2010100135A1 (en) | 2009-03-05 | 2010-09-10 | Ablynx N.V. | Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof |
US9265834B2 (en) | 2009-03-05 | 2016-02-23 | Ablynx N.V. | Stable formulations of polypeptides and uses thereof |
SG175188A1 (en) * | 2009-05-04 | 2011-11-28 | Abbott Biotech Ltd | Stable high protein concentration formulations of human anti-tnf-alpha-antibodies |
PL3438126T3 (pl) | 2009-09-03 | 2021-03-08 | Ablynx N.V. | Stabilne formulacje polipeptydów i ich zastosowanie |
DK2726090T3 (da) * | 2011-07-01 | 2020-01-20 | Biogen Ma Inc | Argininfri tnfr: fc-fusionspolypeptidsammensætninger |
CA2857502C (en) | 2011-11-30 | 2019-08-13 | 3M Innovative Properties Company | Microneedle device including a peptide therapeutic agent and an amino acid and methods of making and using the same |
CA2868401C (en) * | 2012-03-26 | 2021-08-24 | Sanofi | Stable anti-cxcr5 igg4 antibody formulations |
US9592289B2 (en) | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
US8883979B2 (en) | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
US9844594B2 (en) * | 2012-12-18 | 2017-12-19 | Merck Sharp & Dohme Corp. | Liquid formulations for an anti-TNF α antibody |
PE20161413A1 (es) | 2013-11-04 | 2017-01-10 | Stemcentrx Inc | Conjugados de anticuerpo anti-efna4-farmaco |
GB201412658D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
US20160018406A1 (en) * | 2014-07-21 | 2016-01-21 | Unchained Labs Inc. | Determination of Protein Aggregation from the Concentration Dependence of Delta G |
JP7019422B2 (ja) | 2015-04-29 | 2022-02-15 | ラジウス ファーマシューティカルズ,インコーポレイテッド | 癌を治療するための方法 |
GB201601073D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
GB201601075D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies molecules |
GB201601077D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibody molecule |
AU2017313150B2 (en) * | 2016-08-18 | 2023-09-14 | Regeneron Pharmaceuticals, Inc. | Assay for determining potential to self-association of a protein using concentration-dependent self-interaction nanoparticle spectroscopy |
AU2017345490B2 (en) | 2016-10-21 | 2022-07-07 | Amgen Inc. | Pharmaceutical formulations and methods of making the same |
KR102557321B1 (ko) | 2017-01-05 | 2023-07-18 | 래디어스 파마슈티컬스, 인코포레이티드 | Rad1901-2hcl의 다형 형태 |
SG11202013177WA (en) | 2018-07-04 | 2021-01-28 | Radius Pharmaceuticals Inc | Polymorphic forms of rad 1901-2hcl |
WO2022154529A1 (ko) * | 2021-01-14 | 2022-07-21 | 한올바이오파마주식회사 | 안정화제를 사용하지 않고도 안정한, 탄파너셉트를 포함하는 안과용 조성물 |
CN115541895B (zh) * | 2022-11-29 | 2023-05-19 | 天津德祥生物技术股份有限公司 | 一种提高微流控反定检测卡灵敏度的配方液及应用 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3176517D1 (en) | 1980-04-24 | 1987-12-17 | Beecham Group Plc | Beta-lactam compounds, their preparation and use |
GB8518416D0 (en) | 1985-07-22 | 1985-08-29 | Beecham Group Plc | Compounds |
US5869053A (en) | 1988-03-04 | 1999-02-09 | Cancer Research Campaign Technology, Ltd. | 5T4 antigen from human trophoblasts |
US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
EP0852951A1 (de) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
US6306393B1 (en) * | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
EP1012259B1 (en) | 1997-06-04 | 2009-09-30 | Oxford Biomedica (UK) Limited | Tumor targeted vector |
JP3919235B2 (ja) * | 1997-06-13 | 2007-05-23 | ジェネンテク,インコーポレイテッド | 抗体製剤 |
AU2444899A (en) | 1998-01-22 | 1999-08-09 | Astrazeneca Ab | Pharmaceutical formulation comprising an antibody and a citrate buffer |
US20030124119A1 (en) | 1999-12-28 | 2003-07-03 | Tadao Yamazaki | Stable antibody compositions and injection preparations |
JP5485489B2 (ja) * | 2000-08-11 | 2014-05-07 | 中外製薬株式会社 | 抗体含有安定化製剤 |
ES2332402T5 (es) * | 2000-10-12 | 2018-05-14 | Genentech, Inc. | Formulaciones de proteína concentradas de viscosidad reducida |
GB0113179D0 (en) * | 2001-05-31 | 2001-07-25 | Novartis Ag | Organic compounds |
US20050031627A1 (en) * | 2002-01-03 | 2005-02-10 | Mazzola Gregory J | Methods for preparing immunoconjugates |
PL224150B1 (pl) | 2002-05-02 | 2016-11-30 | Wyeth Corp | Kompozycja zawierająca koniugat leku obejmujący pochodne kalicheamycyny i przeciwciało, oraz kompozycja farmaceutyczna ją zawierająca |
CA2490423A1 (en) | 2002-06-21 | 2003-12-31 | Biogen Idec Inc. | Buffered formulations for concentrating antibodies and methods of use thereof |
US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
JP2007528868A (ja) | 2003-08-14 | 2007-10-18 | ワイス | 抗ルイスy抗イディオタイプ抗体およびその使用 |
BRPI0515113A (pt) | 2004-09-10 | 2008-07-01 | Wyeth Corp | anticorpos anti-5t4 humanizados e conjugados de anticorpo anti-5t4/caliqueamicina |
-
2005
- 2005-08-11 TW TW094127308A patent/TW200621282A/zh unknown
- 2005-08-12 AU AU2005272603A patent/AU2005272603A1/en not_active Abandoned
- 2005-08-12 EP EP05803522.1A patent/EP1784219B1/en active Active
- 2005-08-12 MX MX2007001599A patent/MX2007001599A/es unknown
- 2005-08-12 JP JP2007525855A patent/JP4948407B2/ja active Active
- 2005-08-12 KR KR1020077003502A patent/KR20070092197A/ko not_active Application Discontinuation
- 2005-08-12 CA CA002575870A patent/CA2575870A1/en not_active Abandoned
- 2005-08-12 RU RU2007109062/13A patent/RU2007109062A/ru not_active Application Discontinuation
- 2005-08-12 CN CNA2005800274833A patent/CN101022831A/zh active Pending
- 2005-08-12 US US11/203,367 patent/US8871201B2/en active Active
- 2005-08-12 BR BRPI0514340-3A patent/BRPI0514340A/pt not_active IP Right Cessation
- 2005-08-12 ES ES05803522.1T patent/ES2637854T3/es active Active
- 2005-08-12 WO PCT/US2005/028861 patent/WO2006020935A2/en active Application Filing
- 2005-08-16 AR ARP050103456A patent/AR051009A1/es unknown
-
2007
- 2007-02-06 CR CR8904A patent/CR8904A/es not_active Application Discontinuation
- 2007-02-11 IL IL181265A patent/IL181265A0/en unknown
- 2007-02-13 EC EC2007007246A patent/ECSP077246A/es unknown
- 2007-02-19 NO NO20070930A patent/NO20070930L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
US20060115472A1 (en) | 2006-06-01 |
JP4948407B2 (ja) | 2012-06-06 |
US8871201B2 (en) | 2014-10-28 |
IL181265A0 (en) | 2007-07-04 |
CN101022831A (zh) | 2007-08-22 |
BRPI0514340A (pt) | 2008-06-10 |
AU2005272603A1 (en) | 2006-02-23 |
CA2575870A1 (en) | 2006-02-23 |
CR8904A (es) | 2007-08-28 |
MX2007001599A (es) | 2007-04-10 |
KR20070092197A (ko) | 2007-09-12 |
NO20070930L (no) | 2007-05-14 |
JP2008515775A (ja) | 2008-05-15 |
ES2637854T3 (es) | 2017-10-17 |
TW200621282A (en) | 2006-07-01 |
WO2006020935A2 (en) | 2006-02-23 |
AR051009A1 (es) | 2006-12-13 |
EP1784219A4 (en) | 2010-02-17 |
RU2007109062A (ru) | 2008-09-20 |
EP1784219B1 (en) | 2017-05-17 |
WO2006020935A3 (en) | 2007-03-08 |
EP1784219A2 (en) | 2007-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP077246A (es) | Formulaciones Estabilizadoras | |
CY1121461T1 (el) | Συνθεσεις που περιλαμβανουν δυσδιαλυτους στο νερο φαρμακευτικους παραγοντες και αντιμικροβιακους παραγοντες | |
CL2017002488A1 (es) | Formulación farmacéutica estable para administración intratecal que comprende una proteína arilsulfatasa a (asa), sal y un tensoactivo de polisorbato y/o un agente amortiguador, y que además puede contener un agente estabilizante; contenedor que comprende dicha formulación; uso para tratar la enfermedad leucodistrofia metacrómatica (mld). (divisional solicitud 3654-2012) | |
AR059964A1 (es) | Metodos para reducir la aglomeracion de proteina | |
TR201905081T4 (tr) | Protein içeren formülasyonların stabilizasyonu için yararlı bileşimler ve yöntemler. | |
ES2531083T3 (es) | Formulaciones estables de polipéptidos y usos de las mismas | |
CO6382079A2 (es) | Composiciones insecticidas estables a base de sulfoximina | |
CR9620A (es) | Composicion agricola | |
AR047949A1 (es) | Preparacion farmaceutica que comprende un anticuerpo contra el receptor de factor de crecimiento endotelial | |
PE20120342A1 (es) | Formulacion de anticuerpo | |
JP2017222654A5 (es) | ||
ES2513716T3 (es) | Enzimas lecitina-colesteros acitransferasa modificadas | |
PE20070723A1 (es) | Imidazopirazinas como inhibidores de quinasas dependientes de ciclina | |
CO6640258A2 (es) | Formulaciones de anticuerpos de alta concentración | |
PE20070437A1 (es) | FORMULACION ACUOSA hFSH | |
CL2011000255A1 (es) | Composicion liquida que comprende una proteina o polipeptido harpin, un portador acuoso, un agente biocida y opcionalmente un inhibidor de proteasa y surfactante no ionico; metodo para preparar dicha composicion; y metodo para inducir respuesta en una planta por aplicacion de dicha composicion. | |
SV2006002513A (es) | Anticuerpos anti-il-6, composiciones, metodos y usos ref. docket cen5094svnp | |
UY36542A (es) | Formulaciones farmacéuticas para anticuerpos anti-tnf-alfa | |
UA100851C2 (ru) | Средство для борьбы с паразитами на животных | |
EP2598660A4 (en) | COMPOSITIONS FOR STABILIZING DNA, RNA AND PROTEINS IN BLOOD AND OTHER BIODEGRADS DURING TRANSPORT AND STORAGE IN AMBIENT TEMPERATURES | |
NO20034323L (no) | Medisinske aerosolformuleringer | |
MX2007015958A (es) | Composiciones de peptido lkktet y/o lkktnt, y metodos. | |
TW200715962A (en) | Compositions and methods of use | |
CY1118101T1 (el) | Φορεας κυτταρων που περιεχει κολλαγονο | |
EA200800847A1 (ru) | Составы пестицидов с риском кристаллизации и способ их получения |